title: Genomic determinants of cancer immunotherapy.
abstract: Cancer immunotherapies - including therapeutic vaccines, adoptive cell transfer, oncolytic viruses, and immune checkpoint blockade - yield durable responses in many cancer types, but understanding of predictors of response is incomplete. Genomic characterization of human cancers has already contributed to the success of targeted therapies; in cancer immunotherapy, identification of tumor-specific antigens through whole-exome sequencing may be key to designing individualized, highly immunogenic therapeutic vaccines. Additionally, pre-treatment tumor mutational and gene expression signatures can predict which patients are most likely to benefit from cancer immunotherapy. Continued work in harnessing genomic, transcriptomic, and immunological data from clinical cohorts of immunotherapy-treated patients will bring the promises of precision medicine to immuno-oncology.
authors.affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, United States; Broad Institute of MIT and Harvard, Cambridge, MA 02142, United States.
authors.forename: Diana
authors.initials: D
authors.lastname: Miao
authors.affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, United States; Broad Institute of MIT and Harvard, Cambridge, MA 02142, United States; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, MA 02215, United States. Electronic address: eliezerm_vanallen@dfci.harvard.edu.
authors.forename: Eliezer M
authors.initials: EM
authors.lastname: Van Allen
mesh_terms: D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics*; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000235:genetics* / Q000276:immunology / Q000628:therapy*